Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment

Cancer Science

Volumn 101, Issue 4, 2010, Pages 882-888

  Ojima, Hidenori ^a   Yoshikawa, Daitaro ^b   Ino, Yoshihiro ^a   Shimizu, Hiroko ^b   Miyamoto, Masashi ^b   Kokubu, Akiko ^b   Hiraoka, Nobuyoshi ^a   Morofuji, Noriaki ^c   Kondo, Tadashi ^c   Onaya, Hiroaki ^d   Okusaka, Takuji ^e   Shimada, Kazuaki ^f   Sakamoto, Yoshihiro ^f   Esaki, Minoru ^f   Nara, Satoshi ^f   Kosuge, Tomoo ^f   Hirohashi, Setsuo ^a,b   Kanai, Yae ^a   Shibata, Tatsuhiro ^a,b  

^a Pathology Division   (Japan)

^b Cancer Genomics Project   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d NATIONAL CANCER CENTER   (Japan)

^e National Cancer Center   (Japan)

^f NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GEMCITABINE; MELANOMA ANTIGEN FAMILY H 1; MESSENGER RNA; PROTEIN P53; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; CYTOPLASMIC LINKER PROTEIN 170; DEOXYCYTIDINE; DRUG DERIVATIVE; MICROTUBULE ASSOCIATED PROTEIN; TUMOR PROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CELL CULTURE; CLINICAL ARTICLE; CYTOTOXICITY; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IC 50; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR XENOGRAFT; ANIMAL; BILE DUCT TUMOR; BILIARY TRACT TUMOR; GENE EXPRESSION PROFILING; GERMFREE ANIMAL; METABOLISM; MOUSE MUTANT; VALIDATION STUDY;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BILE DUCT NEOPLASMS; BILIARY TRACT NEOPLASMS; DEOXYCYTIDINE; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MICE; MICE, SCID; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; SPECIFIC PATHOGEN-FREE ORGANISMS;

EID: 77957271896     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01462.x     Document Type: Article

References (23)

1. Washburn WK, Lewis WD, Jenkins RL. Aggressive surgical resection for cholangiocarcinoma. Arch Surg 1995; 130: 270-6.
2. Kosuge T, Yamamoto J, Shimada K, Yamasaki S, Makuuchi M. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg 1999; 230: 663-71.
3. Jang JY, Kim SW, Park DJ et al. Actual long-term outcome of extrahepatic bile duct cancer after surgical resection. Ann Surg 2005; 241: 77-84.
4. Sakamoto Y, Kosuge T, Shimada K et al. Prognostic factors of surgical resection in middle and distal bile duct cancer: an analysis of 55 patients concerning the significance of ductal and radial margins. Surgery 2005; 137: 396-402.
5. Ieta K, Tanaka F, Utsunomiya T, Kuwano H, Mori M. CEACAM6 gene expression in intrahepatic cholangiocarcinoma. Br J Cancer 2006; 95: 532-40.
6. Khan SA, Thomas HC, Davidson BR, Taylor Robinson SD. Cholangio-carcinoma. Lancet 2005; 366: 1303-14.
7. Thongprasert S. The role of chemotherapy in cholangiocarcinoma. Ann Oncol 2005; 16 (Suppl 2): ii93-6.
8. Shi X, Liu S, Kleeff J, Friess H, Buchler MW. Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 2002; 62: 354-62.
9. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
10. Nakano Y, Tanno S, Koizumi K et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer 2007; 96: 457-63.
11. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 2004; 23: 1539-48.
12. Mori Iwamoto S, Kuramitsu Y, Ryozawa S et al. Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Int J Oncol 2007; 31: 1345-50.
13. Rosell R, Danenberg KD, Alberola V et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004; 10: 1318-25.
14. Santini D, Perrone G, Vincenzi B et al. Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer. Ann Oncol 2008; 19: 724-8.
15. Ohtaka K, Kohya N, Sato K et al. Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma. Oncol Rep 2008; 20: 279-86.
16. Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 2001; 61: 5544-51.
17. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-7.
18. Barker PA, Salehi A. The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. J Neurosci Res 2002; 67: 705-12.
19. Tsai JR, Chong IW, Chen YH et al. Differential expression profile of MAGE family in non-small-cell lung cancer. Lung Cancer 2007; 56: 185-92.
20. *25-restricted MHC class I ligand from solid tumor tissue. Cancer Biol Ther 2005; 4: 943-8.
21. Tcherpakov M, Bronfman FC, Conticello SG et al. The p75 neurotrophin receptor interacts with multiple MAGE proteins. J Biol Chem 2002; 277: 49101-4.
22. Tooker P, Yen WC, Ng SC et al. Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification. Cancer Res 2007; 67: 4425-33.
23. Olive KP, Jacobetz MA, Davidson CJ et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324: 1457-61.